Radiological Evaluation of Sarcopenia in Patient Received Chemotherapy

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06166134

Enrollment

Registered

2023-12-12

Start date

2024-01-31

Completion date

2025-04-30

Last updated

2023-12-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcopenia

Brief summary

Radiological evaluation of sarcopenia in patients receiving chemotherapy

Detailed description

Evaluation of muscle mass by using sonoelastography and computed tomography

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* all cancer patients receiving chemotherapy referred to radiodiagnosis department for routine examination Patients must be between 18 and

Exclusion criteria

* Previous or current history of any musculoskeletal or neurological disorder including strokes. * Systemic atrophy affecting CNS ( Huntington disease ,hereditary ataxia ,spinal muscular disorder and related syndromes ,post polio syndrome ) * Central nervous system demyelinating disease ( Multiple sclerosis , acute disseminated demyelinated syndromes.. * Corticosteroids undertaken currently or for the past 3 years with doses \>5mg/day.

Design outcomes

Primary

Measure	Time frame	Description
Radiological evaluation of sarcopenia in patients receiving chemotherapy	April 2025	Using sonoelastography and computed tomography in evaluation of muscle mass in patients received chemotherapy by measurement of muscle thickness ,echogencity ,cross sectional area ,fasicle length,pennation angle, strain ratio,shear wave velocity

Contacts

Primary ContactDoaa Maher ebied Maher, Resident

dm953407@gmail.com01050147500

Backup ContactHasan ibrahim Megally, Professor

Hasanibrahim48@yahoo.com01006209584

Outcome results